Finance
“The FDA found mold and significant insect activity at China-based plants (Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co.) that manufacture semaglutide and tirzepatide used in compounded GLP-1 drugs.”
Plain restatementUS FDA inspectors documented mold and insect activity at two named Chinese facilities that produce semaglutide and tirzepatide active pharmaceutical ingredients supplied to the US compounded GLP-1 market.
General information only - not financial advice.
This one largely checks out. FDA inspectors did visit two Chinese plants that make semaglutide and tirzepatide ingredients, and the FDA's own public import alert list confirms Chengdu Shengnuo Biopharm was added on 19 September 2026, meaning its shipments can be detained at the US border. The company's parent confirmed the inspection, an 8-item FDA observation form issued on 27 August 2026, and that it stopped selling peptide ingredients to the US. One detail is overstated: the black mold, dirty floors and "significant insect activity" were documented at Chengdu Shengnuo, while the problems reported at the second plant, Nanjing Chengong, were different and involved buying ingredients from other factories and stamping them as approved without checking the source test results. Also worth noting, the sanitation details come from inspection documents a news organization obtained rather than from a published FDA statement, and an import alert flags a failure to meet manufacturing standards rather than proving any particular batch was contaminated. What remains unknown is whether any compounded medicine that reached patients was affected, and whether the FDA has issued formal warning letters to either firm. General information only, not financial or medical advice.
[drifted from the evidence:] The FDA [drifted from the evidence:] found mold and [drifted from the evidence:] significant insect activity at [drifted from the evidence:] China-based plants (Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co.) that [drifted from the evidence:] manufacture semaglutide and tirzepatide [drifted from the evidence:] used in compounded GLP-1 [drifted from the evidence:] drugs.
[added by the neutral restatement:] US FDA [added by the neutral restatement:] inspectors documented mold and insect activity at [added by the neutral restatement:] two named Chinese facilities that [added by the neutral restatement:] produce semaglutide and tirzepatide [added by the neutral restatement:] active pharmaceutical ingredients supplied to the US compounded GLP-1 [added by the neutral restatement:] market.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- FDA inspectors did conduct on-site inspections at both named Chinese facilities in 2026, Chengdu Shengnuo in August and Nanjing Chengong in September.
- Mold, floor contamination and "significant insect activity" in ceilings were documented at Chengdu Shengnuo, and that exact phrase appears in the reporting of the inspection record.
- Both firms were placed on FDA Import Alert 66-40, which allows their shipments to be detained without physical examination. The Chengdu Shengnuo entry appears on the FDA's own Red List with a published date of 19 September 2026.
- Chengdu Shengnuo's parent company independently confirmed the August inspection, a Form 483 with 8 observations issued 27 August 2026, its addition to the import alert on 19 September 2026, and a halt to US peptide API shipments.
- Both facilities are reported to produce semaglutide and tirzepatide active ingredients, and those ingredients go into compounded versions that have not been through FDA approval review.
- The post's statement that compounded drugs do not undergo the same safety and efficacy review as approved drugs, while facilities are subject to periodic inspection, matches the reporting.
- The claim as worded states that mold and significant insect activity were found "at China-based plants (Chengdu Shengnuo Biopharm Co. and Nanjing Chengong Pharmaceutical Co.)", which reads as both. The reporting places the mold, floor contamination and insect findings at Chengdu Shengnuo, and describes a different category of problem at Nanjing Chengong involving ingredients bought from other factories and certified under Nanjing Chengong's own seal without reviewing the source test data. Collapsing the two sets of findings into one sanitation description overstates the scope of what was documented at the second plant. The post's own caption is more careful than the claim as summarized, since it says black mold was found "at one factory".
- The sanitation findings come from inspection documents obtained by a news organization, not from a published FDA announcement describing them. The publicly posted FDA instrument is the import alert listing, which states a GMP conformance concern and not a finding that any specific batch was contaminated. An import alert is a border detention tool, not a product-contamination determination.
- Whether any finished compounded GLP-1 product sold to patients was affected is not established by the sources found. The import alert addresses the facilities' GMP conformance, not the condition of particular shipments already in the US.
- Whether the FDA has issued a warning letter or a final official action classification for either facility is unresolved; the company disclosure of 22 September 2026 stated none had been received at that point.
- The precise date on which Nanjing Chengong was added to Import Alert 66-40 rests on secondary reporting and was not confirmed against the FDA page in this check.
- The full contents and all observations of both Form 483s are not public in the sources located, so the complete picture of each inspection is not available.
The official FDA record confirms the regulatory action. Import Alert 66-40 is the FDA instrument for detaining drugs without physical examination from firms that have not met drug GMPs, and its China section carries an entry for Chengdu Shengnuo Biopharm Co., Ltd. dated 19 September 2026. The alert's charge is that the article is subject to refusal of admission because the methods and controls used for manufacture, processing, packing or holding of drugs do not appear to conform to current good manufacturing practices. The company side corroborates it. Shengnuo Biotech disclosed that its wholly owned subsidiary underwent an FDA on-site inspection in August 2026, that on 27 August the inspection team issued a Form FDA 483 with 8 observations, that the company submitted an initial response and corrective measures, and that on checking the FDA website the subsidiary had been added to the 66-40 import list on 19 September 2026, with no warning letter received. The company reported 167 million yuan of US sales in the first half of 2026, 32.83% of revenue for the period, and committed to stop all peptide API sales and shipments to the US market until the FDA restriction is lifted. On the inspection findings themselves, the reporting separates the two plants. At Chengdu Shengnuo, inspectors noted black mold on equipment, "gross contamination" on floors and "significant insect activity" in the ceilings; a September visit to Nanjing Chengong found workers buying active ingredients produced by other manufacturers and then applying Nanjing Chengong's own approval seal to those materials. At Nanjing Chengong, employees sourced active ingredients from third-party factories and certified them under the company's own approval stamp, and made no effort to examine the third-party factories' test results before certifying the ingredients as acceptable. Inspectors at Chengdu Shengnuo also observed quality-control staff running documents across the hall and stuffing them into lockers, and watched workers pour product samples down sinks; that plant also had mold and significant insect activity in the ceilings. On the GLP-1 link: both companies made semaglutide and tirzepatide, the active ingredients in Novo Nordisk's and Eli Lilly's weight-loss drugs, and the companies made those ingredients for custom versions that regulators have not approved or reviewed for safety and effectiveness. On inspection history, Nanjing Chengong was last inspected in March 2025 and Chengdu Shengnuo in September 2023.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Did the FDA actually find mold and insects at these plants?
Yes, but at only one of the two plants. Inspectors documented black mold, floor contamination and significant insect activity in the ceilings at Chengdu Shengnuo Biopharm. Nanjing Chengong had a different problem: workers bought ingredients from other factories and certified them under their own approval stamp without checking the source test results.
What does being placed on FDA Import Alert 66-40 actually mean?
It means shipments from that facility can be detained at the US border without physical examination because its manufacturing methods and controls do not appear to meet current good manufacturing practices. It is a border detention tool, not a finding that any specific batch was contaminated.
Did the companies involved confirm any of this?
Chengdu Shengnuo's parent company, Shengnuo Biotech, confirmed the August 2026 inspection, an 8-item FDA observation form issued August 27, its addition to the import alert list on September 19, and said it has stopped selling peptide ingredients to the US market.
Were any compounded GLP-1 drugs that reached patients affected?
The investigation did not establish this. The import alert addresses the facilities' manufacturing standards, not the condition of any particular shipment already sold in the US.
Has the FDA issued formal warning letters to either company?
This is unresolved. As of the company's September 22, 2026 disclosure, no warning letter had been received, and the investigation did not find confirmation of one since.